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PCARDIOVASCULAR GENOMIC MEDICINE
Role of Genetic Analysis in the
Management of Patients With Arrhythmogenic
Right Ventricular Dysplasia/Cardiomyopathy
Srijita Sen-Chowdhry, MBBS, MD, MRCP, Petros Syrris, BSC, PHD,
William J. McKenna, MD, DSC, FRCP, FACC
London, United Kingdom
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a recognized cause of sudden cardiac death, which
may be prevented by timely detection and intervention. Clinical diagnosis of ARVC is fraught with difficulties in
both index cases and relatives owing to the nonspecific nature of associated features, diverse phenotypic mani-
festations, and a lack of conspicuous abnormalities in the early, “concealed” phase. During the past 7 years,
researchers have isolated causative mutations in several components of the desmosome, shedding light on the
molecular mechanisms underlying the disease and offering the promise of genetic testing as a diagnostic tool.
Sequence analysis is likely to be the mainstay of genotyping in ARVC because of marked allelic heterogeneity,
frequent “private” mutations, and digenicity in a minority, highlighting the importance of comprehensive genetic
screening. The main technical obstacle to implementation of genotyping in clinical practice will be the prohibi-
tive costs of performing sequence analysis of a genomic region exceeding 40 kb. Nevertheless, the success rate
of genotyping in ARVC is of the order of 40%, and key clinical applications include confirmatory testing of index
cases to facilitate interpretation of borderline investigations and cascade screening of families. The latter is par-
ticularly attractive in ARVC, because age-related penetrance otherwise demands lifelong clinical reassessment of
extended families. A role for genetic analysis in prognostication is more tenuous at present, but increasing iden-
tification of individuals with early and familial disease underscores the need for a definitive risk stratification
algorithm in this population. (J Am Coll Cardiol 2007;50:1813–21) © 2007 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.08.008b
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derhaps more so than any other inherited cardiovascu-
ar disorder, arrhythmogenic right ventricular dysplasia/
ardiomyopathy (ARVD/C) has undergone a paradigm
hift in the 30 years since its name was first coined (1). The
alient structural finding of fibrofatty replacement of the
ight ventricular myocardium was originally thought to
ccur as a developmental anomaly, leading to the use of the
erm dysplasia. Key clinical and pathological studies subse-
uently led to reclassification of the disease as a cardiomyop-
thy with a familial preponderance (2–4). Involvement of the
eft ventricle is now commonly recognized (5–7). The most
ignificant advance of the current decade, however, has been
dentification of causative mutations in components of the
esmosome (Table 1), the specialized intercellular junctions
hat anchor intermediate filaments to the cytoplasmic mem-
rom Cardiology in the Young, The Heart Hospital, University College London,
ondon, United Kingdom. Sources of funding: British Heart Foundation, European
ommission 5th Framework Program (ARVC/D project, QLG1-CT-2000-01091).
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ccepted August 6, 2007.rane in adjoining cells, thereby forming a supportive
etwork (Fig. 1) (8–30). Besides offering the promise of
eoxyribonucleic acid–based diagnosis, the gene identifica-
ion studies spurred the desmosomal model of ARVD/C
8), which has provided the first glimpse into the molecular
nderpinning of the disease.
Desmosomes are most prevalent in tissues exposed to
rictional and shear stress, such as the myocardium and
pithelium, where they play a key role in imparting me-
hanical strength, both via cell–cell adhesion and through
ransmission of force between the junctional complex and
he intermediate filaments in the cytoskeleton (Fig. 1) (8).
he underlying premise of the model is that defects in
omponents of desmosomes may compromise their func-
ion, predisposing to myocyte detachment and death. Sig-
ificant myocyte loss may be accompanied by an inflamma-
ory response. The regenerative capacity of the myocardium
s limited, necessitating repair by fibrofatty substitution.
ather than being a gradual and continuous process, extension
f the disease to previously unaffected regions of the myocar-
ium may occur during intermittent “hot phases,” periodic
xacerbations of an otherwise-quiescent disease, sometimes
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Clinical Role of Genetic Analysis in ARVC November 6, 2007:1813–21accompanied by a transient in-
crease in arrhythmic activity. It is
probable that the majority of
“hot phases” are clinically silent,
whereas others are accompanied
by mild symptomatic flare-ups;
rarely, however, the outcome
may be an unheralded arrhyth-
mic event in an individual with
previously stable disease.
Of the 2 additional genes
linked with ARVD/C, the car-
iac ryanodine receptor gene RyR2 causes a distinct clinical
ntity, ARVD2, characterized by juvenile sudden cardiac
eath and effort-induced polymorphic ventricular tachycar-
ia (31). The typical electrocardiographic features of
RVD/C do not occur, and structural abnormalities are
imited to mild regional wall motion abnormalities of the
ight ventricle, with preservation of global systolic function.
s such, the phenotype of ARVD2 bears closer resemblance
o familial catecholaminergic polymorphic ventricular
achycardia, which is also associated with mutations in
yR2 (8,14).
The second extradesmosomal gene implicated in
RVD/C is transforming growth factor (TGF)-3, which
timulates production of components of the extracellular
atrix. Mutations in the untranslated regions of TGF-3,
redicted to result in overexpression, have been isolated in
ne large family and an unrelated proband with ARVD1
inkage (32,33). That 2 ARVD1 kindreds lacked mutations
n TGF-3 is a caveat in gauging its overall contribution to
he genetic profile of ARVD/C (8,33). Nevertheless, in
itro studies suggest that TGF- may modulate expression
f desmosomal genes, lending further support to the hy-
othesis that impaired desmosomal function is the “final
ommon pathway” in ARVD/C (14,32).
Although genetic studies have provided important in-
ights into the pathogenesis of ARVD/C, the anticipated
ole of genotyping in the clinical arena has not yet been
ealized. This article aims to outline both the current status
Abbreviations
and Acronyms
ARVD/C  arrhythmogenic
right ventricular dysplasia/
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
PKP  plakophilin
TGF  transforming growth
factor
ummary of Desmosomal Genes Implicated in AVRD/C
Table 1 Summary of Desmosomal Genes Implicated in AVRD/C
Gene (Symbol),
Locus
Exons (n),
Transcript Size (kb)
Mode of
Inheritance
Number of
Reported Mutati
Plakoglobin (JUP)
17q21
14, 2.4 AR 1
Desmoplakin (DSP)
6p24
24, 8.9 AD
AR
10
3
Plakophilin (PKP)-2
12p11
14, 2.6 AD
AR
50
1
Desmoglein (DSG)-2
18q12
15, 3.4 AD 20
Desmocollin (DSC)-2
18q12
17, 3.1 AD 3D  autosomal dominant; AR  autosomal recessive; ARVD/C  arrhythmogenic right ventricular dyspf molecular genetic analysis as a clinical tool in ARVD/C
nd the prospects for expansion of its scope in the future.
linical Applicability of Genetic Testing
espite the enthusiasm with which the discovery of new
enes is generally hailed, assimilation of genetic analysis into
linical practice tends to be a slow and arduous process (34).
ypertrophic cardiomyopathy is the most common inher-
ted cardiovascular disease, with an estimated prevalence of
in 500 in the population. Contemporary estimates suggest
hat around 60% of index cases with hypertrophic cardio-
yopathy harbor mutations in one of the known disease-
ausing genes, and that more than 80% of these individuals
ould be successfully genotyped by screening 2 genes in
articular: -myosin heavy chain and myosin binding pro-
ein C (34). Nevertheless, for a variety of reasons pertaining
o accessibility, allocation of limited resources, and per-
Type of Reported
Mutations Associated Phenotype References
Deletion Naxos disease (1)
Various
Missense
Nonsense
Deletion
ARVC
ARVC, skin disorder, woolly hair
ARVC, skin disorder, woolly hair
Carvajal syndrome
(2–6)
(7)
(8)
(9)
Various
Cryptic splice site
ARVC
ARVC
(5,10–17)
Various ARVC (5,18–20)
Deletion, insertion, splice site ARVC (21,22)
Figure 1 Schematic of Desmosomal Structure
The desmosomal cadherins, desmoglein (DSG)-2 and desmocollin (DSC)-2 com-
prise the transmembrane component of the desmosomal complex. Their extra-
cellular domains interface directly with their counterparts on neighboring cells.
The intracellular portions of the desmosomal cadherins interact with proteins
of the armadillo family: junctional plakoglobin (JUP) and plakophilin (PKP)-2,
which in turn bind to the N-terminal domain of desmoplakin (DSP). At its
C-terminal, DSP anchors desmin intermediate filaments to the cell surface.
Modified from Sen-Chowdhry et al. (8).onslasia/cardiomyopathy.
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November 6, 2007:1813–21 Clinical Role of Genetic Analysis in ARVCeived cost-effectiveness, genetic testing is offered to fami-
ies with hypertrophic cardiomyopathy in only a few spe-
ialized centers.
Genotyping in ARVD/C lags behind the status quo in
ypertrophic cardiomyopathy, but is quickly catching up
nd, as a result of the difficulties inherent in clinical
iagnosis (35), may ultimately take on a far more important
ole therein than in other inherited cardiovascular disorders.
riori and Napolitano (34) have proposed a scoring system
Table 2) to determine the clinical applicability of genotyp-
ng in Mendelian diseases, based on both technical and
linical criteria. According to the guidelines, genetic testing
s indicated in diseases achieving a score of 3, which
nclude hypertrophic cardiomyopathy, long-QT syndrome,
ilated cardiomyopathy in association with conduction de-
ects, and familial catecholaminergic polymorphic ventricu-
ar tachycardia. At the other end of the spectrum are
iseases in which genotyping remains a research activity,
ith limited scope for clinical application. Dilated cardio-
yopathy falls in this latter category, attaining a score of
1, largely because of marked genetic heterogeneity and the
onsequently poor pick-up rate from genotyping. In disor-
ers scoring from 1 to 3, of which ARVD/C and Brugada
yndrome are examples, genetic testing has a potential
linical role that remains to be fully defined (34). The main
actors influencing this categorization warrant further dis-
ussion in the specific context of ARVD/C.
hat Proportion of Patients
ith ARVD/C Can Be Genotyped?
he clinical feasibility of genetic testing is dependent in
arge part on its success rate in the target population. In a
ecent UK referral center sample, mutation screening of the
riori-Napolitano Criteria to Definepplicability of Genetic Testing in Clinical Practice
Table 2 Priori-Napolitano Criteria to DefineApplicability of Genetic Testing in Clinical Practice
Criteria Points
Technical aspects
Percentage of genotyped patients
50 3
30 to 49 2
10 to 29 1
Unknown or 10 0
Size of the genomic region to screen, kb
1 1
1 to 3 0
3 to 8 0.5
8 to 13 1
13 1.5
Clinical aspects
A, Presymptomatic diagnosis is clinically relevant 0.5
B, Identification of silent carriers is clinically relevant 0.5
C, Results influence risk stratification 0.5
D, Results influence therapy/lifestyle 0.5
E, Reproductive counseling is clinically justified 0.5seprinted, with permission, from Priori and Napolitano (34).desmosomal genes hitherto implicated in ARVD/C
Table 1) in 69 unrelated individuals allowed successful
enotyping of 20 (30%) (7). No mutations were identified
n plakoglobin. In a contemporaneous Italian series, muta-
ion screening of the “big 3” ARVD/C genes (i.e., desmo-
lakin, plakophilin [PKP]-2, and desmoglein-2, in order of
requency) allowed successful genotyping of 32 of 80 unre-
ated index cases (40%). Inclusion of TGF-3 effected a
odest increase in the detection rate to 42.5% (26,36).
A key departure from the United Kingdom–Italian expe-
ience in other published cohorts has been the frequency of
utations in PKP-2 (7,36). Gerull et al. (18) first reported
7% prevalence of PKP-2 defects in 120 unrelated index
ases with ARVD/C. The proportion was still greater in the
.S. cohort described by Dalal et al. (22), in which 25 of 58
nrelated ARVD/C probands had PKP-2 mutations. van
intelen et al. (20) reported a similar 43% frequency of
KP-2 mutations in their series of 56 ARVD/C index cases
n the Netherlands, which exceeds the overall pick-up rate
rom genotyping in the United Kingdom and Italian co-
orts. The most striking finding in the Dutch study was that
6 of 23 (70%) of probands with demonstrable familial disease
ad mutations in PKP-2, suggesting that plakophilin-2 is the
ajor determinant of familial ARVD/C in the Netherlands
20).
Dalal et al. (22) failed to identify common haplotypes
mong individuals with identical PKP-2 mutations in the
.S. study. In the Dutch cohort, however, haplotype anal-
sis of index cases with 4 apparently recurrent PKP-2
utations revealed allele sharing, which is consistent with
ounder effects (20). Founder mutations have previously
een recognized in the Dutch population in conjunction
ith benign familial cholestasis, type I diabetes mellitus,
-DOPA-responsive dystonia, familial hypercholester-
lemia, protein C deficiency, and hypertrophic cardiomyop-
thy (the 2373insG mutation in the myosin binding protein C
ene) (20,37). As noted by van Tintelen et al. (20), the 70%
ick-up rate frommutation screening of a single gene is unique
mong inherited myocardial diseases, strengthening the case
or clinical use of genetic testing in the management of familial
RVD/C in the Dutch population. A similar argument can be
ade in favor of screening the Naxos population for carriers
f the 2157del2 mutation in plakoglobin, for which a
ounder effect has also been demonstrated (9).
In the absence of founder mutations, as in the original
tudy by Gerull et al. (18) and the subsequent American
eries (22), an alternative explanation must be sought for the
iscrepancy in the prevalence of PKP-2 mutations. Differ-
nces in subject selection may be at least partly responsible.
t most referral centers, individuals with symptomatic
rrhythmia of right ventricular origin account for the ma-
ority of index cases. In comparison, the United Kingdom
ohort included a much greater proportion of cases identi-
ed by familial evaluation after the death of the proband
rom pathologically proven ARVD/C (7). It has also been
uggested that some of the numerous missense changes may
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Clinical Role of Genetic Analysis in ARVC November 6, 2007:1813–21e pathogenic only when accompanied by additional genetic
olymorphisms (7). Assuming, however, that all published
utations are pathogenic in isolation, the pooled results
rom four recent genotype–phenotype correlation studies
Table 3) yield a pick-up rate of 40% from mutation
creening of the known ARVD/C genes, with the exception
f RyR2.
Although the inclusion of polymorphisms may have
esulted in overestimation of the success rate of genotyping,
he 40% figure may equally represent an underestimate, for
number of reasons. No data were available regarding the
revalence of mutations in desmoplakin or desmoglein-2 in
he Dutch and U.S. cohorts screened for PKP-2 disease
20,22,36). Additional single-gene studies from the United
ingdom, Italy, and U.S. were omitted from the pooled
ata in Table 3 because the overlap with other published
ohorts from the same centers was not known (12,19,27–
0). Furthermore, existing studies reflect early experience
ith genotyping in ARVD/C and incorporate only a small
roportion of the patient population at each major referral
enter. Finally, gene identification studies in ARVD/C are
ngoing, with additional components of the desmosome-
ntermediate filament complex and associated proteins the
rimary candidates. Comprehensive screening of all known
nd candidate genes is likely to place the detection rate
rmly in the 40% to 50% range, sufficient to justify clinical
pplication in the near to immediate future.
hat Technical Considerations Influence the
ost-Effectiveness of Genetic Testing in ARVD/C?
n the Priori-Napolitano scoring system, the size of the
oding regions of the genes implicated in a particular disease
erves as an indirect estimate of the cost of genotyping (34).
lthough this measure is useful as a preliminary guide, the
echnical factors impacting on the cost-effectiveness of
enetic testing in ARVD/C merit more detailed explo-
ation. Genetic analysis may be considered a 2-step
rocess, entailing the initial search for a causative muta-
ion(s) in an affected individual, and subsequent confir-
atory or predictive testing for the presence of a known
utation in relatives.
Marked allelic diversity appears to be the rule for the
ain ARVD/C genes. Furthermore, although the number
Pooled Results From Major Genetic Studies to EFrom Genotyping in Arrhythmog ni Right Ventr
Table 3 Pooled Results From Major GeneticFrom Genotyping in Arrhythmogenic
Study Location
Number
Screened PKP-2
London, United Kingdom 69 6
the Netherlands 56 24
Padua, Italy 80 11
U.S. 58 25
Composite 263 66
Overall detection rateDSC  desmocollin; DSG  desmoglein; DSP  desmoplakin; PKP  plakopf mutations so far reported in desmocollin-2 and plako-
lobin are too small to allow comment, current experience
ndicates a preponderance of private mutations in the “big 3”
enes in ARVD/C, a scenario comparable with that of the
eta-myosin heavy chain gene in hypertrophic cardiomyop-
thy (8–30,38). Frequent private mutations are contingent
pon a relatively high spontaneous mutation rate, although this
lone is not sufficient to account for their apparent failure to
erpetuate in the gene pool and become “common.” One
ossibility is that most of these mutations occur de novo,
ith increased penetrance and high lethality resulting in
enetic death. Clinical experience, however, suggests
therwise; ARVD/C is familial rather than sporadic in
he majority of cases (7) and sudden death a relatively rare
ccurrence in a typical kindred. The alternative and more
lausible explanation is that these mutations are far more
revalent in the general population than presently appreci-
ted, and that milder phenotypic manifestations may be under-
ecognized.
Recurrent or “common” ARVD/C mutations are few but
oteworthy, particularly in PKP-2, where R79X, 2146-
GC, S140F, and S50fsX110 are key examples (18,19). In
he absence of founder effects, however, the proportion of
ommon mutations in the ARVD/C population is too limited
o advocate screening for specific defects as a first-line ap-
roach. Neither do there appear to be any mutational hotspots
n the “big 3” genes, with defects occurring in the N-terminus,
od, and C-terminus of desmoplakin, every exon of PKP-2,
nd spread through the functional domains of desmoglein-2
8–30). The upshot is that in attempting to genotype
RVD/C patients, no shortcut can obviate the need for
ystematic sequencing of the desmosomal genes, although it
ay be prudent to begin the search with the “big 3” genes,
articularly PKP-2.
The burden on both resources and effort does not end
ere, however. An additional corollary of frequent private
utations is a substantial likelihood of isolating a novel
utation, with no information available regarding its patho-
enicity. In general, it may be safe to assume a causative role
or deletions, frameshift, and nonsense mutations, but the
ame does not apply to single amino acid substitutions.
nce a novel missense change has been identified, and its
bsence from ethnically matched control subjects verified, it
ate Overall Detection Rater Dysplasia/Cardiomyop thy
ies to Estimate Overall Detection Rate
t Ventricular Dysplasia/Cardiomyopathy
P DSG-2 DSC-2 TGF-3 Total
5 2 20
24
8 2 34
25
13 2 2 103
39.2%stimicula
Stud
Righ
DS
7
13
20hilin; TGF  transforming growth factor.
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November 6, 2007:1813–21 Clinical Role of Genetic Analysis in ARVCecomes necessary to screen other family members and
stablish causality through correlation of clinical and genetic
ndings. Finally, emerging data suggest that an important
inority of ARVD/C patients are homozygous, double-
eterozygous, or compound-heterozygous (7,25,27). Di-
enic inheritance in ARVD/C is consistent with experience
n both long QT-syndrome and hypertrophic cardiomyop-
thy (38) and underscores the importance of screening every
oding region of all known disease-causing genes, even after
solation of a putative pathogenic mutation.
Confirmatory and predictive testing in relatives with and
ithout clinical features of the disease is more straightfor-
ard. Allelic heterogeneity precludes any role for genetic
robes, however, and although polymerase chain reaction-
estriction fragment length polymorphism analysis is rela-
ively inexpensive, utility is limited to mutations that fall
ithin restriction sites. Consequently, direct bidirectional
equencing of the exon containing the defect remains the
referred approach for known-mutation detection in
RVD/C, affording the highest diagnostic accuracy of
ny available technique.
Sequence analysis is therefore the mainstay of both gene
dentification studies and predictive testing in ARVD/C.
espite its reliability, genetic sequencing is an effort and
ost-intensive process, particularly when the genes are large,
s is the case in ARVD/C. Comprehensive screening of all
desmosomal genes, including flanking intronic sequences
or each exon, requires coverage of a genomic region of
pproximately 40 kb, posing the single greatest obstacle to
ost-effective genetic testing for ARVD/C in a clinical setting.
evertheless, it is likely that the clinical benefits of genetic
nalysis will ultimately outweigh the technical drawbacks.
s Presymptomatic
iagnosis Clinically Relevant?
resymptomatic diagnosis is the aspect of ARVD/C in
hich genotyping is most likely to find a niche. That sudden
ardiac death is the first clinical manifestation of the disease
n more than 50% of index cases may be the most compel-
ing argument in favor of adopting a proactive approach to
amilial evaluation (39,40). One of the foremost clinical
hallenges in ARVD/C is timely diagnosis of the so-called
concealed” phase, during which a dearth of symptoms may
elie significant arrhythmic risk (1,35). Recent studies
uggest that asymptomatic status does not imply subclinical
isease (7,41), and presymptomatic diagnosis may therefore
e possible in a significant proportion of family members
hrough standard, noninvasive clinical assessment. Genetic
nalysis, however, is invaluable in cascade screening of
amilies, the benefits of which are 2-fold: first, in affording
lifetime of reassurance to gene-negative relatives, who will
onstitute approximately 50% of those tested and, second, in
llowing clinical resources to be targeted to proven gene-
arriers. A subset of genetically affected individuals will have
n unremarkable evaluation but remain at risk of “hot lhases,” underscoring the importance of aggressively inves-
igating new onset symptoms (8,42). The availability of
olecular diagnosis intensifies the need for a definitive
olution to the ensuing challenge, that of reliable risk
tratification in early ARVD/C.
s Identification of Silent
arriers Clinically Relevant?
he clinical manifestations of ARVD/C may develop at any
ge, although childhood cases are rare and onset during the
ubertal growth spurt is common. Where the age-distribution
f ARVD/C differs most noticeably from hypertrophic cardio-
yopathy is in the prevalence of late onset disease. Recogni-
ion of delayed morphological conversion in hypertrophic
ardiomyopathy has prompted revision of the guidelines for
amilial evaluation; whereas relatives attaining physical ma-
urity were previously presumed to be genetically unaffected,
eassessment every 5 years throughout adulthood is now
dvocated (43). Nevertheless, late onset hypertrophic car-
iomyopathy is found primarily in conjunction with muta-
ions in myosin binding protein C and is otherwise the
xception rather than the rule (44). Conversely, age-related
enetrance may be a defining characteristic of ARVD/C
41), which may be related at a molecular level to progres-
ive exposure to mechanical stress. Long-term endurance
thletes appear to have structurally severe forms of the
isease (7), a finding supported by animal studies in which
ndurance training accelerated the development of right
entricular dysfunction and arrhythmia in heterozygous
lakoglobin-deficient mice (45). The disease may progress
ore slowly in individuals leading a sedentary life, with
yocardial injury accumulating as part of the aging process.
Silent carriers, in the truest sense of the term, are
enetically affected individuals who remain free from clinical
anifestations of the disease throughout their lifetimes.
ecause symptoms are a poor guide to disease severity (7),
etermining the prevalence of silent carriers in ARVD/C
ill require lifelong clinical follow-up of gene-positive
ndividuals, with re-evaluation at suitable intervals. Al-
hough this approach is to be encouraged in ARVD/C
ecause of age-related penetrance (41) and the “hot-phase”
henomenon, long-term outcomes in genotyped individuals
ith autosomal-dominant ARVD/C must be awaited.
From a pragmatic standpoint, silent carriers are individuals
ho, at any point in time, lack evidence of clinically penetrant
isease but retain the capacity to transmit the disease to their
hildren. As a corollary of variable penetrance (8,41), silent
arriers as such are frequent in ARVD/C and may, in small
amilies, give the false impression of sporadic disease. Referral
enters specializing in familial disease have responded to this
roblem by routinely offering assessment to second- and
ometimes third-degree relatives which, when continued long-
erm to avoid missing occult disease, poses a significant burden
n clinical resources (35). No less concerning is the psycho-
ogical impact on relatives, who must reconcile themselves to
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Clinical Role of Genetic Analysis in ARVC November 6, 2007:1813–21ifelong screening without any prospect of definitive reassur-
nce, on the off-chance that they may be gene-carriers. In
RVD/C, the alternative is no more palatable because it
ntails presuming that a normal clinical work-up indicates
ene-negative status in adult relatives, and accepting that a
inority of them or their children may present catastrophically
ith an arrhythmic event. Cascade screening based on geno-
yping comes to the fore here, by obviating the need to test the
hildren of gene-negative individuals, and identifying silent
arriers whose children can in turn be offered genetic analysis.
s Confirmatory
esting Clinically Relevant?
onfirmatory testing is defined herein as the use of geno-
yping to corroborate clinical suspicion of disease in an
ndex case. As such, it should be distinguished from genetic
creening to verify clinical status in relatives with borderline
nvestigations. The neurodegenerative disorder Huntington’s
isease is a classic example of a condition in which confir-
atory testing is of clinical relevance. When faced with a
atient exhibiting cognitive, motor, or psychiatric symptoms
uggestive of Huntington’s disease, neurologists may request
enetic analysis to determine the presence of the causative
xpanded trinucleotide repeat on the short arm of chromo-
ome 4. The number of CAG repeats provides a definitive
nswer; 35 excludes the disease, whereas 36 to 40 indi-
ates incomplete and 40 fully penetrant disease (46). In
ontrast to Huntington’s, most inherited cardiovascular
isorders are genetically heterogeneous and hence less ame-
able to confirmatory testing. Marfan’s disease, caused by
utations in the gene encoding the matrix protein fibrillin 1,
epresents a possible exception; however, more than 90% of
ffected individuals have private mutations, and the prohib-
tive cost of sequencing all 65 exons has limited the utility of
enotyping as a clinical tool (47). Equally, in Marfan’s as in
ost other inherited cardiovascular diseases, the phenotype
n index cases is often clear-cut and the diagnosis readily
stablished on clinical grounds alone.
For these reasons at least, confirmatory testing is not
ncluded as a distinct criterion in the Priori-Napolitano
coring system (34). The myriad caveats notwithstanding,
owever, confirmatory testing has the potential to play a key
ole in ARVD/C because of the unique challenges that
linical diagnosis may pose (35). In everyday clinical prac-
ice, arrhythmia of right ventricular origin remains the
rimary reason to suspect ARVD/C and idiopathic right
entricular outflow tract tachycardia the main differential
iagnosis (35). Isolated right heart failure is a far less common
resentation. With growing awareness of ARVD/C among
linicians, typical electrocardiographic abnormalities such as
ight precordial T-wave inversion may also arouse suspicion,
hether in the context of arrhythmic symptoms or as an
ncidental finding. It will be apparent, however, that the
linical features of disease are nonspecific; even right ven- dricular aneurysms and epsilon waves, both highly charac-
eristic of ARVD/C, may also occur in sarcoidosis (48).
The 1994 Task Force diagnostic guidelines were designed
o facilitate clinical diagnosis by excluding phenocopies (1).
eveloped through expert consensus in the pregenetics era,
hen experience with ARVD/C was limited to symptom-
tic index cases and sudden death victims, the criteria fulfill
heir aim of standardizing diagnosis, with high specificity
ttained at the cost of reduced sensitivity (35,39). Modifi-
ations have been proposed to enhance their sensitivity in
he context of familial disease (39). Early diagnosis in index
ases, however, remains an unsolved problem. Much atten-
ion has recently focused on imaging techniques, such as
ardiovascular magnetic resonance and 3-dimensional
nd/or contrast-enhanced echocardiography. Both almost
ertainly have an important role to play in early detection,
ut high diagnostic accuracy is difficult to achieve when
nterpreting subtle wall motion abnormalities in the thin-
alled, trabeculated, pyramidal right ventricle (49).
Furthermore, emerging data suggest that ventricular ar-
hythmia in ARVD/C may occur in the absence of histo-
ogical substrate. Kaplan et al. (50) describe a 5-year-old girl
ith Naxos disease who demonstrated frequent ventricular
xtrasystoles (14,000 in 24 h) and depolarization abnor-
alities characteristic of ARVD/C, including localized
RS prolongation and epsilon waves. After her death from
eukemia 2 years later, extensive macroscopic and histolog-
cal assessment of her heart failed to identify fibrofatty
eplacement or other features of ARVD/C, leukemic infil-
rates, or degenerative features suggestive of chemotherapy-
elated injury. However, immunofluorescent studies and
lectron microscopy revealed reduced localization of mutant
lakoglobin to cell–cell junctions, diminished expression of
he gap junction protein connexin-43, and a decreased in
he number and size of gap junctions (50). Impaired
echanical coupling from desmosomal dysfunction is pos-
ulated to compromise electrical coupling through gap
unction remodeling (50).
More recently, Kirchhof et al. (45) have reported spon-
aneous ventricular tachycardia of right ventricular origin in
eterozygous plakoglobin-deficient mice without evidence
f either abnormal histology or altered connexin-43 expres-
ion. The mechanism underlying the arrhythmia remains
nexplained, although mechanoelectrical feedback is one
ossibility. The clinical implications are more readily appar-
nt: patients with ventricular arrhythmia may have under-
ying ARVD/C without there being any other clinical
ointer to the diagnosis. Follow-up of these patients is
herefore imperative, even if treatment modalities succeed in
uppressing both symptoms and arrhythmia (35). In centers
ith a particular interest in early ARVD/C, familial assess-
ent may be a first-line strategy to facilitate diagnosis in the
ndex case. This approach involves consolidating isolated
henotypic features in family members to attain a unifying
iagnosis and is sometimes successful, but will clearly
isappoint in the case of a de novo mutation in the proband.
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November 6, 2007:1813–21 Clinical Role of Genetic Analysis in ARVCThus, despite its modest pick-up rate of 40% to 50% and
he size of the genomic region requiring sequence analysis,
creening of the desmosomal genes may eventually become
art of the clinical work-up for an individual with suspected
RVD/C, although a negative result will not exclude the
isease. Identification of a desmosomal mutation may also
e of value in the exclusion of phenocopies of ARVD/C. At
he time of framing of the Task Force criteria, left ventric-
lar involvement was considered an endstage complication
f the disease, occurring after the onset of global right
entricular dysfunction, and leading ultimately to biven-
ricular pump failure (1). Both pathological and clinical
tudies since then have highlighted left ventricular involve-
ent as a common feature of ARVD/C (5,6), which may
ccur in the setting of preserved right ventricular function
7). Three distinct patterns of disease expression have
ecently been identified: the well-known “classic” pheno-
ype, in which the predilection for the right ventricle persists
hroughout the disease course; “biventricular,” with parallel
nvolvement of both ventricles; and the increasingly recog-
ized “left-dominant” variant. Arrhythmia of left ventricular
rigin and lateral ECG abnormalities are observed in the
biventricular” and “left-dominant” forms, which may be
isdiagnosed as dilated cardiomyopathy. The main distinc-
ion is that dilated cardiomyopathy typically presents with
eart failure, whereas symptoms of arrhythmia predominate
mong patients with arrhythmogenic cardiomyopathy (7,8).
n late presenters, clarification of the diagnosis may depend
n identifying features such as prominent wall motion
bnormalities, aneurysms, and myocardial fat, but the iso-
ation of a desmosomal mutation is particularly persuasive.
arly data suggest that the extent of left ventricular involve-
ent may be more marked in individuals with desmoplakin
isease or chain-termination mutations, but the prognostic
mpact thereof is not currently known (7).
oes Genotyping Influence
ifestyle, Risk Stratification, or Therapy?
n the basis of currently available data, any attempt to
auge the potential influence of genotyping on risk stratifi-
ation and therapy is likely to be premature. In accordance
ith the desmosomal model, it may be prudent for proven
RVD/C gene carriers to avoid highly strenuous activity,
articularly endurance training (7,8,45). Without knowl-
dge of the penetrance of a mutation, however, some are apt
o consider such blanket recommendations unnecessarily
estrictive. Similarly, the dual influences of incomplete pen-
trance and variable expressivity confound the adverse prog-
ostic impact of carrying an ARVD/C mutation to the point
here neither prenatal diagnosis nor proscriptive reproductive
ounseling are clinically justified, particularly as effective ther-
pies are available (8).
In contrast to hypertrophic cardiomyopathy, a family
istory of premature sudden death does not appear to be a
ey indicator of adverse prognosis in ARVD/C (51), sug-
westing that the ultimate role of genotyping in risk stratifi-
ation will be limited. Variations in disease expression
etween families carrying the same mutation, and among
embers of the same family, suggest that modifier genes
nd environmental influences contribute significantly to the
verall phenotype in ARVD/C (7,24,41). Nevertheless,
utations at the ARVD5 locus, for which the gene respon-
ible remains unidentified, appear to be particularly malig-
ant, and DNA haplotyping has been advocated to facilitate
arly diagnosis and prophylactic placement of an implant-
ble cardioverter-defibrillator (ICD) (52). Dalal et al. (22)
onducted a systematic comparison of ARVD/C patients
ith (n  25) and without (n  33) mutations in PKP-2.
atients harboring PKP-2 mutations had earlier onset of
oth symptoms and ventricular arrhythmia compared to
hose who did not, although the incidence of appropriate
CD interventions was similar in the 2 subgroups. Analysis
f ICD firing rates allowed identification of a number of risk
actors in patients without PKP-2 mutations, including
nducibility at electrophysiological study, the presence of
revious spontaneous ventricular tachycardia, and diffuse
ight ventricular disease. Curiously, these predictors did not
nfluence the frequency of ICD interventions among PKP-
–positive patients (22). Numbers, however, remain small
nd validation in large-scale genotype–phenotype correla-
ion studies is awaited.
onclusions
omprehensive mutation screening of all known and can-
idate genes is liable to yield a success rate of at least 40%
n ARVD/C. The major technical obstacle to its implemen-
ation in clinical practice will be the prohibitive costs of
erforming sequence analysis of a genomic region exceeding
0 kb. The frequency of private mutations in ARVD/C
amilies, coupled with digenicity in a minority, nonetheless
uggests that sequence analysis will remain the mainstay of
oth gene identification studies and predictive testing. In
he clinical arena, genotyping will be of most value in
nabling cascade screening of relatives, particularly at-
ractive in ARVD/C because variable and age-related
enetrance otherwise necessitate lifelong clinical re-
ssessment of extended families. Both the subtlety of
linical abnormalities in early ARVD/C and the diverse
henotypic manifestations of the disease, which include
eft ventricular arrhythmia and ECG changes, suggest a
otential role for genotyping in confirmatory testing of
ndex cases. At present, data from genotype–phenotype
tudies are too limited to permit speculation on the possible
mpact of genetic analysis on risk stratification or therapy.
eprint requests and correspondence: Dr. William J. McKenna,
ardiology in the Young, The Heart Hospital, 16-18 Westmore-
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